Drug intelligence / Profile preview

B-3E01

Development stage: Preclinical
Lead developer: Yifan Pharmaceutical

Overview

B-3E01 is a biologic drug candidate currently in preclinical development by Yifan Pharmaceutical for the treatment of diabetes. It is part of a broader portfolio of metabolic disease assets within Yifan's pipeline, which includes other biologic candidates such as B-3E02, B-3E03, and B-3E10. While the specific molecular target and mechanism of action (such as whether it is an insulin analog or a GLP-1 receptor agonist) have not been publicly disclosed in the company's high-level pipeline summaries, it is categorized as a biologic therapy aimed at glycemic control.

Beyond the preview

Go deeper on B-3E01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-3E01.

Explore the full profile